Literature DB >> 25741403

Real-life effectiveness of topical vitamin d and corticosteroid combination therapy in psoriasis : moving beyond clinical trials.

Joshua Zeichner1.   

Abstract

To provide successful care for psoriasis patients, treatments must be efficacious and safe as well as improve the patients' overall well-being. Efficacy and safety are generally established by randomized, controlled clinical trials. However, because of the rigid conditions under which randomized, controlled clinical trials are conducted, they do not reflect patient experience in real-life clinical practice; that is, they do not measure treatment effectiveness in the real world. Factors such as adherence to therapy, treatment satisfaction, and quality of life may be rated unrealistically high in randomized, controlled clinical trials. Observational studies using real-life patient populations, and capturing patient-reported outcomes, are useful at better assessing a treatment's effectiveness. Healthcare professionals and payers may gain valuable insights from patient-reported outcomes data that can be used in making treatment decisions. For localized plaque psoriasis, topical vitamin D analog and corticosteroid combination therapy is recommended as a first-line treatment. This commentary addresses the concept of clinical trial efficacy versus real-life effectiveness in psoriasis treatment using vitamin D and corticosteroid topical combination therapy as a model.

Entities:  

Year:  2015        PMID: 25741403      PMCID: PMC4345933     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  9 in total

1.  A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis.

Authors:  T A Luger; F Cambazard; F G Larsen; M Bourcier; G Gupta; F Clonier; P Kidson; N H Shear
Journal:  Dermatology       Date:  2008-09-12       Impact factor: 5.366

Review 2.  Psoriasis: epidemiology, clinical features, and quality of life.

Authors:  R G B Langley; G G Krueger; C E M Griffiths
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

3.  Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies.

Authors:  Alan Menter; Neil J Korman; Craig A Elmets; Steven R Feldman; Joel M Gelfand; Kenneth B Gordon; Alice Gottlieb; John Y M Koo; Mark Lebwohl; Henry W Lim; Abby S Van Voorhees; Karl R Beutner; Reva Bhushan
Journal:  J Am Acad Dermatol       Date:  2009-02-13       Impact factor: 11.527

4.  Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial.

Authors:  Alan Menter; Linda Stein Gold; Michael Bukhalo; Steven Grekin; Steven Kempers; Brent M Boyce; Cecilia Ganslandt; John Villumsen; Mark Lebwohl
Journal:  J Drugs Dermatol       Date:  2013-01       Impact factor: 2.114

5.  A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.

Authors:  P C M van de Kerkhof; V Hoffmann; A Anstey; L Barnes; C Bolduc; K Reich; S Saari; S Segaert; L Vaillant
Journal:  Br J Dermatol       Date:  2008-11-25       Impact factor: 9.302

6.  Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: 4- and 12-week interim results from the PRO-long study.

Authors:  J Lambert; C W Hol; J Vink
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-02-17       Impact factor: 6.166

7.  Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis.

Authors:  Kim A Papp; Lyn Guenther; Bernard Boyden; Frederik Grønhøj Larsen; Rauno J Harvima; Jean Jacques Guilhou; Roland Kaufmann; Sarah Rogers; Peter C M van de Kerkhof; Leif I Hanssen; Eva Tegner; Günter Burg; David Talbot; Anthony Chu
Journal:  J Am Acad Dermatol       Date:  2003-01       Impact factor: 11.527

8.  Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance.

Authors: 
Journal:  Health Qual Life Outcomes       Date:  2006-10-11       Impact factor: 3.186

9.  A primer on effectiveness and efficacy trials.

Authors:  Amit G Singal; Peter D R Higgins; Akbar K Waljee
Journal:  Clin Transl Gastroenterol       Date:  2014-01-02       Impact factor: 4.488

  9 in total
  3 in total

1.  Tobacco Industry Research on Nicotine Replacement Therapy: "If Anyone Is Going to Take Away Our Business It Should Be Us".

Authors:  Dorie Apollonio; Stanton A Glantz
Journal:  Am J Public Health       Date:  2017-08-17       Impact factor: 9.308

2.  Safety and efficacy of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II, open-label trial.

Authors:  M Seyger; W Abramovits; M Liljedahl; M N Hoejen; J Teng
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-02-19       Impact factor: 6.166

3.  A study of the use of drugs in patients suffering from psoriasis and their impact on quality of life.

Authors:  V V Karamata; A M Gandhi; P P Patel; A Sutaria; M K Desai
Journal:  Indian J Pharmacol       Date:  2017 Jan-Feb       Impact factor: 1.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.